⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157583 | 0.82 | — | — | |
| SCHEMBL16087758 | 0.81 | TSHR (0.46) | — | |
| SCHEMBL13133071 | 0.81 | TSHR (0.46) | — | |
| SCHEMBL19359790 | 0.80 | TSHR (0.40) | — | |
| SCHEMBL2695801 | 0.80 | TSHR (0.40) | — | |
| SCHEMBL216060 | 0.79 | — | — | |
| SCHEMBL15610527 | 0.79 | — | — | |
| SCHEMBL16212808 | 0.79 | — | — | |
| SCHEMBL187616 | 0.79 | — | — | |
| SCHEMBL15998255 | 0.78 | TSHR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772502-B2 | Alkylsulfinyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-07-08 | — | — | US | claimed |
| EP-2635124-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | Romark Laboratories, L.C. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061190-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2012-05-10 | — | — | WO | claimed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | claimed |
| US-20120108591-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | claimed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | claimed |
| US-8163911-B2 | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-24 | — | — | US | claimed |
| WO-2011005595-A2 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | claimed |
| US-20100261677-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | claimed |
| US-5710159-A | IMIDAZOLIN-2-YLAMINOPROPOXY)ISOXAZOL-5-CARBONYLAMINO-2 -BENZYLOXYCARBONYLAMINOPROPIONIC ACID AS ANTIINFLAMMATORY AGENTS, BONE DEGRADATION, TUMORS, METASTASES AND THROMBOSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-20 | — | — | US | claimed |
| WO-1997048395-A1 | IONTOPHORETIC DELIVERY OF INTEGRIN INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997033887-A1 | SPIROCYCLE INTEGRIN INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-09-18 | — | — | WO | claimed |
| US-5668159-A | ANTICOAGULANTS FOR CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-09-16 | — | — | US | claimed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | claimed |
| WO-1996037482-A1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | claimed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | claimed |